Clinical Study. Oncology 2010;79: DOI: /
|
|
- Phyllis Claribel Johns
- 6 years ago
- Views:
Transcription
1 Oncology Clinicl Study DOI: 10.59/ Received: June 24, 2010 Accepted: July 27, 2010 Published online: Mrch 1, 20 Prospective Multicenter Rndomized Phse III Study of Weekly versus Stndrd Docetxel plus Doxorubicin (D4) for First-Line Tretment of Metsttic Brest Cncer Hns-Jochim Stemmler Ndi Hrbeck c Isolde Gröll de River e Ursul Vehling Kiser f Gerhrd Ruthe g Wolfgng Abenhrdt d Almut Artmnn c Hrld Sommer b Hns-Gerd Meerpohl h Mrion Kiechle c Volker Heinemnn Deprtment of Internl Medicine III, Klinikum Grosshdern, nd b Deprtment of Gynecology nd Obstetrics, Klinikum Innenstdt, Ludwig Mximilin University of Munich, c Deprtment of Gynecology nd Obstetrics, Technische Universität München, nd d Onkologische Prxis, Munich, e Deprtment of Gynecology nd Obstetrics, Klinikum Ebersberg, Ebersberg, f Onkologische Prxis, Lndshut, g Deprtment of Gynecology nd Obstetrics, Schlossbergklinik Oberstufen, Oberstufen, nd h Deprtment of Gynecology nd Obstetrics, St.-Vincenzius-Kliniken AG, Krlsruhe, Germny Key Words Docetxel Weekly ppliction Metsttic brest cncer Combintion chemotherpy Abstrct Purpose: Previous phse II studies hve indicted gretly reduced hemtotoxicity of docetxel-bsed regimens dministered on weekly schedules. The present tril ws initited to compre the toxicity nd efficcy of weekly docetxel versus its stndrd 3-weekly ppliction in combintion with doxorubicin. Methods: Ptients previously untreted with chemotherpy for metsttic disese were recruited. Inclusion criteri were ge! 65 yers or Krnofsky Performnce Sttus of %. All ptients in the D4 study received doxorubicin (50 mg/m 2 ) on the first dy of tretment in ddition to docetxel given either t 3-weekly dose of 75 mg/m 2 every 3 weeks (q3w) or t weekly dose of 35 mg/m 2 (dys 1, 8, nd 15; q4w). Tretment ws continued until mximum of 8 cycles, uncceptble toxicity, or disese pro- gression. All ptients received stndrd corticosteroid prophylxis. Results: Since interim nlysis showed filure to rech significnt difference for the primry endpoint (hemtotoxicity, i.e. leukopeni), the study ws closed ccording to the study protocol (85 of 242 ptients). A lower-thnexpected rte of leukopeni 6 grde 3 ws observed in the stndrd rm of the D4 study compred to the weekly schedule (per-ptient nlysis: 61.9% q3w vs. 65.1% q1w; p ). Grde 3 nd grde 4 fever, dirrhe, nd infections occurred more frequently in the stndrd rm, wheres neurotoxicity nd skin/nil disorders were observed more frequently in the weekly rm. Except for fever, none of these differences reched level of significnce. Dose delys, dose reductions, nd the rte of omitted doses were incresed in the weekly rm. The overll response rte ws 44.2% in the weekly rm compred to 52.4% in the stndrd rm (p = 0.52). Time to progression ws 6.2 (q1w) versus 10.3 (q3w) months (p = H.-J.S. nd N.H. contributed eqully to this pper. Fx E-Mil krger@krger.ch 20 S. Krger AG, Bsel /10/ $26.00/0 Accessible online t: PD Dr. H.J. Stemmler, Medicl Deprtment III (Hemtology-Oncology) Klinikum Grosshdern, University of Munich Mrchioninistrsse 15, DE Munich (Germny) Tel , Fx E-Mil med.uni-muenchen.de
2 0.36), nd overll survivl ws 20.5 (q1w) versus 28.7 (q3w) months (p = 0.98). Conclusion: The present dt support the fesibility of both weekly nd 3-weekly ppliction of docetxel in combintion with doxorubicin. Nevertheless, given tht leukopeni ws similr in both rms nd the efficcy prmeters were t lest numericlly inferior with the weekly schedule, stndrd 3-weekly ppliction seems to be preferble for ptients requiring combintion chemotherpy. Copyright 20 S. Krger AG, Bsel Introduction Docetxel (Txotere ; Snofi-Aventis, Frnkfurt, Germny) is one of the most effective ntitumor gents currently vilble for the tretment of erly brest cncer s well s metsttic brest cncer (MBC). In MBC, when compred with the gold stndrd doxorubicin, docetxel hs shown significntly superior response rte (RR; 47.8 vs. 33.3%; p = 0.008) nd trend towrds prolonged time to progression (TTP; 26 weeks vs. 21 weeks) [1]. After filure with nthrcycline-contining chemotherpy, single-gent docetxel hs demonstrted superior results when compred with mitomycin/vinblstine [RR, TTP, nd overll survivl (OS)] or methotrexte/5-fluorourcil (RR nd TTP), nd it hs shown equivlent efficcy when compred with vinorelbine/5-fluorourcil (RR, TTP, nd OS) [2 4]. When docetxel is dministered t stndrd dose of 100 mg/m 2 [every 3 weeks (q3w)], 70 90% of ptients develop grde 3/4 neutropeni [1]. Insted of dose reductions, one strtegy to reduce toxicity without growth fctor support is to pply docetxel on weekly schedule. Severl studies hve indicted tht severe hemtotoxicity (grde 3/4) could lrgely be prevented t weekly doses of less thn 40 mg/m 2 without impired efficcy in the first- or secondline setting [5 9]. Moreover, the fvorble toxicity profile of weekly scheduled docetxel ws confirmed in 2 rndomized phse II/III trils without inferior results regrding TTP or OS [10, ]. A further rtionle for weekly docetxel might be tht stndrd-dose single-gent doce - txel (100 mg/m 2 q3w) frequently needs to be djusted to 75 mg/m 2 in pretreted, unfit, or elderly ptients [12]. The reltively low rte of severe leukopeni ssocited with weekly scheduled docetxel my permit combintion with other cytotoxic gents. Txnes nd nthrcyclines re considered mong the most ctive single gents for the tretment of erly brest cncer s well s MBC. Consequently, their combined use is logicl step in the serch for highly effective chemotherpy combintions. Phse II trils which hve investigted such n nthrcycline/txne combintion given on 3-week schedule hve shown n improved RR of 46 88% without higher rte of crdiotoxicity [13 16]. The high RR were ttined in ptients with unfvorble prognostic fctors (multiple metsttic sites, viscerl involvement, nd prior exposure to djuvnt chemotherpy). However, the dose-limiting fctor in these trils ws leukopeni. Phse II trils investigting weekly scheduled nthrcycline/txne combintion proved efficient nd hd mngeble toxicity profile [17, 18]. Considering these prior experiences, the D4 study ws designed to evlute the toxicity nd efficcy of weekly docetxel/doxorubicin regimen compred to 3-weekly scheduled stndrd scheme in younger nd mediclly fit ptients with MBC. Ptients nd Methods Ptient Selection The tretment protocol ws pproved by the locl ethics committee nd ll ptients gve their written informed consent before tretment ws strted. Ptients with MBC, none of whom hd received chemotherpy for metsttic disese, were recruited for the tril. Ptients were required to hve Krnofsky Performnce Sttus (KPS) 670% nd n ge between 18 nd 65 yers. Ptients who hd received prior djuvnt nthrcyclines t cumultive dose mg/m 2 or who hd positive history of coronry hert disese with crdic dysfunction or n impired left ventriculr ejection frction (EF) were not eligible; crdic EF hd to be norml ( 6 50%). Ptients were required to hve histologiclly proven MBC, bidimensionlly mesurble disese, nd n nticipted survivl of t lest 12 weeks. Prior to study entry, heptic, renl, nd hemtologicl functions hd to be dequte [leukocyte count 63.0! 10 9 /l, pltelets 6100! 10 9 /l, hemoglobin 6 8 g/dl, bilirubin ^ 1.25 times the norml rnge, lnine minotrnsferse:sprtte minotrnsferse (ALT:AST) rtio ^ 3 times the norml rnge, nd lkline phosphtse ^ 2.5 times the norml rnge]. Ptients with bone metstses only nd/or steroid (estrogen nd/or progesterone) receptor expression without prior endocrine therpy were not eligible for the tril. Additionl exclusion criteri were ctive infections, rdiotherpy of more thn 25% of mrrow-contining bone, cliniclly overt brin metstses, previous neuropthy 6 grde II, or history of second mlignncy other thn resected bsl cell nd/or squmous cell crcinom of the skin. Ptients were not eligible for study enrolment if they were pregnnt or lctting, or if they refused effective contrception. Tretment Regimen Docetxel ws dissolved in 100 ml of 0.9% sline nd given by intrvenous (i.v.) infusion over 30 min (35 mg/m 2 weekly) or 60 min (75 mg/m 2 q3w), respectively. Doxorubicin (50 mg/m 2 ) ws dissolved in 250 ml of 0.9% sline nd infused for 60 min. D4 Combined Weekly Docetxel for MBC 205
3 Ptients in the D4 study received doxorubicin (50 mg/m 2 ) on the first dy of tretment in ddition to docetxel given either t 3-weekly dose of 75 mg/m 2 q3w or t weekly dose of 35 mg/m 2 (dys 1, 8, nd 15; q4w). Tretment ws continued until mximum of 8 cycles, uncceptble toxicity, or disese progression. All ptients received stndrd corticosteroid prophylxis, ntiemetics (routinely 5HT3 ntgonists), nd growth fctors (which were llowed t ny point) ccording to the locl stndrds. Dose Adjustments In cse of myelosuppression on the dy of the plnned tretment (leukocytes ^ 2,000/ l nd pltelets ^ 50,000/ l), further drug dministrtion ws postponed for 1 week until bone mrrow recovery occurred (leukocytes 6 2,000/ l nd pltelets 6 50,000/ l). If there ws no recovery within the dditionl rest of 1 week, the ptient ws excluded from the study. A reduced dose of ech drug ( 25%) ws pplied in cse of leukocyte count between 2,000/ l nd 3,000/ l nd pltelet count between 50,000/ l nd 100,000/ l. A full dose of docetxel nd doxorubicin ws dministered if the blood counts hd risen to leukocytes 6 3,000/ l nd pltelets 6 100,000/ l. Ptients were excluded from the tril in cse of nonhemtologicl toxicity 6 grde 3 (excluding lopeci nd nuse/vomiting). Dose reductions of 25% (for doxorubicin nd docetxel) were required in cse of hemtologicl toxicity grde 3 or 4 complicted by fever, infection, or both. Moreover, reduced dose ( 20%) ws required in cse of grde 3 dirrhe or mucositis. D t C o l l e c t i o n Drug dministrtion, KPS, nd toxicity or dverse events were recorded fter every cycle of tretment. Weekly blood counts were performed. Febrile neutropeni ws defined s fever ( 6 38 C) with grde 4 neutropeni requiring i.v. ntibiotics nd/or hospitliztion without documented infection. Fluid retention included peripherl edem nd/or pleurl nd pericrdil effusions. Toxicity ws grded ccording to the Ntionl Cncer Institute s Common Toxicity Criteri (NCI CTC 2.0) [19]. Imging studies using ultrsonogrphy, computed tomogrphy (CT), or mgnetic resonnce imging (MRI) were performed fter every 2 cycles of tretment. Crdic Surveillnce Ptients in the D4 tril underwent echocrdiogrphy prior to study entry nd then fter every second cycle. An EF 650% ws considered norml. Ptients were excluded from the study if the EF decresed to ^ 50% or decresed by 6 10% compred to the bseline vlue. Response Evlution In ll ptients, tumors were mesured by imging procedures (ultrsound, CT, or MRI) within 14 dys prior to study entry nd subsequently fter every 2 cycles of tretment. A stndrd evlution comprised of history, physicl exmintion, nd routine lbortory tests (including complete blood cell count, chemistry profile, nd electrolyte determintion) ws performed before ech tretment. Ptient response ws ssessed ccording to stndrd WHO criteri s follows: Complete response (CR) ws defined s the disppernce of ll known disese s determined by 2 observtions not less thn 4 weeks prt, while prtil response (PR) ws defined s decrese of t lest 50% in the sum of the products of the lrgest perpendiculr dimeters of ll mesurble lesions s determined by 2 observtions not less thn 4 weeks prt. Stble disese (SD), lsting t lest 6 weeks from the strt of the study (i.e. the first drug dministrtion), ws defined s! 50% decrese nd! 25% increse in the sum of the products of the lrgest perpendiculr dimeters of ll mesurble lesions. Progressive disese (PD) ws 1 25% increse in the size of t lest 1 bidimensionlly or unidimensionlly mesurble lesion or the ppernce of new lesion. The occurrence of pleurl effusion ws considered sign of progression if verified by positive cytology. Study Endpoints nd Sttistics The primry study endpoint ws hemtotoxicity (leukopeni). Assuming grde 3 nd grde 4 hemtotoxicity rtes of 70 95% for the stndrd regimen nd 10 20% for the weekly regimen, the clculted smple size for the primry endpoint ws 40 ptients (20 for ech tretment rm), with sttisticl power of 80% using 5% level of significnce (Fishers s exct test). An interim nlysis ws plnned in 80 recruited ptients (40 for ech tretment rm) for the primry endpoint using 1 = nd 2 = s the levels of significnce (O Brien nd Fleming sequentil design). For the secondry endpoint (TTP) the clculted smple size ws 242 ptients, with the ssumption of the noninferiority of the weekly schedule (TTP q3w = 10.3 months nd TTP q1w = 9.3 months) (O Brien nd Fleming sequentil design). Smple sizes were clculted using NCSS/PASS 2000 softwre. Further secondry endpoints were OS nd RR. TTP ws determined by the intervl between the initition of therpy nd the first dte tht disese progression ws objectively documented. OS ws mesured from the dte of the strt of tretment to the dte of deth from ny cuse. All ptients were included in the (intent-to-tret) nlysis of TTP nd survivl. The probbilities of survivl nd TTP were estimted by Kpln-Meier nlysis, nd confidence intervls for the RR were clculted using methods for exct binominl confidence intervls [20, 21]. R e s u l t s Ptient Chrcteristics Ptients were recruited between July 2001 nd August Since the scheduled interim nlysis showed filure to rech sttisticl significnce for the primry endpoint in the finl nlysis, the D4 study ws closed before chieving its trget recruitment (85 of 242 ptients). The medin observtion time ws 18.7 months (rnge ). The ptients chrcteristics re presented in tble 1. Toxicity A summry of the hemtologicl nd nonhemtologicl toxicities is given in tble 2. A comprbly low rte of leukopeni, i.e. 6 grde 3, which ws rther similr to the one observed in the weekly rm, ws observed in the 206 Stemmler et l.
4 stndrd q3w rm of the D4 study (per-ptient nlysis: 61.9% q3w vs. 65.1% q1w; p ) even though the rte of grde 4 leukopeni ws nerly twice the number in the stndrd rm (38.1% q3w vs q1w). Fever ws more frequently observed in the 3-week regimen (21.4% q3w vs. 4.7% q1w; p = 0.03). Moreover, grde 3 nd grde 4 dirrhe nd infections occurred more frequently in the stndrd rm, wheres neurotoxicity (7.0% q1w vs. 0% q3w; p ) nd skin/nil disorders (.6% q1w vs. 0% q3w; p = 0.06) were observed more frequently in the weekly rm. Except for fever, none of these differences reched the 0.05 level of significnce. Other nonhemtologicl toxicities ( 6 grde 3) were comprble between the 2 schedules. The medin number of pplied cycles ws 6 (rnge 1 8) for the stndrd rm nd 5 (rnge 1 8) for the weekly rm. The medin durtion of tretment ws dys (rnge 1 170) for the stndrd rm nd 151 dys (rnge 1 245) for the weekly schedule. Dose reductions nd delyed nd omitted doses within cycle were required significntly more often in ptients rndomized to weekly docetxel (p! 0.001, ech). There ws significnt difference regrding the percentge of the intended drug delivered within cycle between the 2 regimens (99.2% stndrd dose vs. 78.3% weekly dose). Ef f ic c y The overll RR ws 48.2% (95% CI ), with 3 CR, 38 PR, 22 SD, nd 15 PD (intent-to-tret nlysis) ( tble 3 ). Seven ptients were not evluble. The overll RR ws comprble between the groups of stndrd or weekly scheduled docetxel (44.2% q1w vs. 52.4% q3w; p = 0.52). Moreover, there ws numericl but not significnt difference with regrd to TTP (6.2 months q1w vs months q3w; p = 0.36) nd OS (20.5 months q1w vs months q3w; p = 0.98) ( tble 4 ; fig. 1 ). A summry of the response nd survivl dt is given in tbles 3 nd 4 nd in figure 1. Discussion Numerous phse II studies hve shown considerbly reduced hemtotoxicity, but stble efficcy, of weekly scheduled docetxel in the first- or second-line setting of MBC [5 9]. These dt hve been confirmed in 2 rndomized phse II/III trils by River et l. [10] nd Tbernero et l. []. This rther low rte of severe leukopeni ssocited with weekly scheduled docetxel my permit its combintion with nthrcyclines. Both gents re Tble 1. Ptient chrcteristics Chrcteristics D4 (n = 85) q1 w q3w Ptients Age, yers Medin Rnge KPS, % Medin Rnge Estrogen nd progesterone receptor sttus Positive Negtive Unknown Menopusl sttus Premenopusl Postmenopusl HER-2 sttus Positive (IHC 3+ or 2+ nd FISH+) Negtive (IHC 0 or 1+ or 2+ nd FISH ) Unknown Mesurble disese sites Lung Liver Lymph nodes Skin Skeleton Disese sites per ptient, n Prior tretment Adjuvnt chemotherpy (including nthrcyclines) Adjuvnt hormonl therpy considered mong the most ctive single gents for the tretment of MBC. Consequently, their combined use is logicl step in the serch for highly effective chemotherpy combintions. Previous phse II trils investigted 3-week scheduled nthrcycline/txne regimen with impressive high RR of 46 88% [13 16]. However, the dose-limiting fctor in these trils ws leukopeni, leding to the initition of phse II trils investigting weekly nthrcycline/txne combintion. Such studies hve demonstrted efficcy with mngeble toxicity profile [17, 18]. Gmucci et l. [17] reported considerbly low rte of 6grde 3 neutropeni of 16% of ptients who received first-line weekly epirubicin (25 mg/m 2 ) nd docetxel (25 mg/m 2 ) for MBC. The regimen ws quite effective, with n RR of D4 Combined Weekly Docetxel for MBC 207
5 Tble 2. Toxicity profile (per-ptient nlysis): hemtologicl nd nonhemtologicl toxicity by NCI CTC grde A (q3w), % B (q1w), % p vlue (fter dichotomiztion / 3) Hemtologicl toxicity Anemi >0.05 Leukopeni >0.05 Thrombocytopeni >0.05 Nonhemtologicl toxicity Alopeci >0.05 AP >0.05 Arrhythmis >0.05 Bilirubin >0.05 Constiption >0.05 Cretinine >0.05 Dirrhe >0.05 Fever Fluid retention >0.05 Gstrointestinl symptoms >0.05 GGT >0.05 Infections >0.05 Mucositis >0.05 Musculoskeletl disorders >0.05 Nuse nd vomiting >0.05 Neurotoxicity >0.05 Edem >0.05 Pin >0.05 Skin nd nil disorders >0.05 Tble 3. Efficcy: RR (intent-to-tret nlysis) D4 CR PR SD PD Not evluble RR, % 95% CI, % p All ptients (n = 85) q1w group (n = 43) q3w group (n = 42) RR q1w versus q3w. 60% nd medin OS of 25 months. Moreover, Perez- Mng et l. [18] reported on phse II study which investigted combintion of doxorubicin (50 mg/m 2 q4w) nd weekly scheduled docetxel (36 mg/m 2 dys 1, 8, nd 15; q4w) for loclly dvnced or metsttic brest cncer (first line). A consistently low rte of severe neutropeni ( 6 grde 3) ws reported (! 10% febrile neutropeni) nd RR were considerbly high mong loclly dvnced nd metstsized ptients, i.e. 93 nd 64%, respectively. Lcking rndomized dt, the D4 study ws designed to evlute the toxicity nd efficcy of weekly docetxel/ doxorubicin regimen compred to the 3-weekly stndrd scheme in younger nd mediclly fit MBC ptients. In brief, in the primry sfety endpoint of the D4 study significnt difference ws not reched. The ssumption of mrkedly reduced hemtotoxicity within the weekly schedule ws not verified. Surprisingly, the rte of leukopeni ( 6 grde 3) ws rther low in the stndrd rm, wheres it ws not reduced t ll in the weekly rm (61.9% q3w vs. 65.1% q1w; p ). Since the primry endpoint ws not reched, the D4 study ws closed fter n interim nlysis ccording to the study protocol (85 of Stemmler et l.
6 Fig. 1. TTP nd OS in the D4 study. mo = Months. Proportion of TTP nd survivl D4: medin OS q3w 28.7 mo q1w 20.5 mo p = 0.98 D4: medin TTP q3w 10.3 mo q1w 6.2 mo p = ,080 1,260 1,440 Time (dys) Tble 4. Efficcy: TTP nd OS D4 q3w q1w p vlue medin rnge medin rnge (log-rnk test) TTP, months OS, months Tble 5. Toxicity profile: dose modifictions All q3w q1w p vlue (n = 432) (n = 236) (n = 196) Cycles Dose reductions 130 (30.09) 55 (23.31) 75 (38.27) <0.001 Delyed doses 86 (19.91) 25 (10.59) 61 (31.12) <0.001 Omitted doses 43 (9.95) 0 43 (21.94) <0.001 Percentge of intended drug delivery <0.001 R eductions within cycle; dt given s n (%). ptients). The presumption of gretly reduced hemtotoxicity in the weekly rm ws bsed on the studies of Perez-Mng et l. [17] nd Gmucci et l. [18]. Both investigted weekly scheduled nthrcycline/txne combintion which hs shown reduced rte of leukopeni. Thus, we cnnot provide vluble explntion for the reltively high numbers of grde 3 nd 4 leukopeni in the weekly docetxel rm observed in our study. With regrd to nonhemtologicl toxicities, i.e. skin nd nil disorders, the known sequele of weekly dministered docetxel were incresed in ptients who were rndomized to the weekly schedule (.6% q1w vs. 0% q3w; p = 0.06). Moreover, even more surprisingly, the rte of reduced, delyed, or omitted doses within cycle ws significntly higher mong ptients receiving weekly docetxel s follows: 38.3 versus 23.3%, 31.1 versus 10.6%, nd 21.9 versus 0%, respectively (q1w vs. q3w; p! 0.001, ech). Therefore, the percentge of the intended drug delivered within cycle ws gretly reduced in the weekly rm (77.3% q1w vs. 90.3% q3w) ( tble 5 ). It is suspected tht this lesser dose contributed to mesurble loss of efficcy even though none of the differences in RR, TTP, nd OS reched the level of significnce. The RR ws 44.2% in the weekly rm compred to 52.4% under the stndrd regimen (p = 0.52). Moreover, the medin TTP nd OS were numericlly inferior in ptients who received the weekly schedule. TTP ws 6.2 (q1w) versus 10.3 (q3w) months (p = 0.36), nd OS ws 20.5 (q1w) versus 28.7 (q3w) months (p = 0.98). A finl sttement regrding efficcy is restricted by the limittion tht the clculted smple size for the secondry endpoints (TTP nd OS) ws not reched in the D4 study. Moreover, imblnces regrding the cumultive nthrcycline dose between both study rms my contribute to bis regrding the efficcy prmeters (50 mg/m 2 doxorubicin pplied q3w in the stndrd rm vs. q4w in the weekly rm ). Nevertheless, the study ws ter- D4 Combined Weekly Docetxel for MBC 209
7 minted fter the interim nlysis due to filure to rech sttisticl significnce in the primry endpoint (leukopeni). The striking trend towrds n improved TTP nd OS within the stndrd rm of the D4 study (q3w vs. q1w: TTP 10.3 vs. 6.2 months nd OS 28.7 vs months) my be t lest prtilly explined by the bove mentioned limittions. In conclusion, the dt of the D4 study hve surprisingly but unmistkbly shown tht leukopeni could not be prevented by weekly schedule of docetxel/nthrcycline combintion despite phse II dt indicting gretly reduced hemtotoxicity in fvor of the weekly dministrtion of docetxel. In view of the t lest numericlly reduced efficcy in the weekly rm s well s the substntilly incresed nonhemtologicl side effects, this pproch seems not to merit further investigtion. References 1 Chn S, Friedrichs K, Noel D, Pinter T, Vn Belle S, Vorobiof D, Durte R, Gil Gil M, Bodrogi I, Murry E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, Gonzlez Mnch R, Richrdson G, Wlpole E, Ronzoni M, Murwsky M, Alkl M, Riv A, Crown J: Prospective rndomized tril of docetxel versus doxorubicin in ptients with metsttic brest cncer. J Clin Oncol 1999; 17: Bonneterre J, Roche H, Monnier A, Gustll JP, Nmer M, Frgeot P, Assdourin S: Docetxel versus 5-fluorourcil plus vinorelbine in metsttic brest cncer fter nthrcycline therpy filure. Br J Cncer 2002; 87: Nbholtz JM, Senn HJ, Bezwod WR, Melnychuk D, Deschenes L, Doum J, Vndenberg TA, Rpoport B, Rosso R, Trillet-Lenoir V, Drbl J, Molino A, Nortier JW, Richel DJ, Ngyklni T, Siedlecki P, Wilking N, Genot JY, Hupperets PS, Pnnuti F, Skrlos D, Tomik EM, Murwsky M, Alkl M, Apro M, et l: Prospective rndomized tril of docetxel versus mitomycin plus vinblstine in ptients with metsttic brest cncer progressing despite previous nthrcyclinecontining chemotherpy 304 study group. J Clin Oncol 1999; 17: Sjostrom J, Blomqvist C, Mouridsen H, Pluznsk A, Ottosson-Lonn S, Bengtsson NO, Ostenstd B, Mjlnd I, Plm-Sjovll M, Wist E, Vlvere V, Anderson H, Bergh J: Docetxel compred with sequentil methotrexte nd 5-fluorourcil in ptients with dvnced brest cncer fter nthrcycline filure: rndomised phse III study with crossover on progression by the Scndinvin Brest Group. Eur J Cncer 1999; 35: Hinsworth JD, Burris HA 3rd, Greco FA: Weekly dministrtion of docetxel (Txotere): summry of clinicl dt. Semin Oncol 1999; 26: Aihr T, Kim Y, Tktsuk Y: Phse II study of weekly docetxel in ptients with metsttic brest cncer. Ann Oncol 2002; 13: Stemmler J, Mir W, Stuch M, Ppke J, Deutsch G, Abenhrdt W, Dorn B, Kentenich C, Mlekmohmmdi M, Jckisch C, Leinung S, Brudler O, Vehling-Kiser U, Stmp J, Heinemnn V: High efficcy nd low toxicity of weekly docetxel given s first-line tretment for metsttic brest cncer. Oncology 2005; 68: Stemmler HJ, Gutschow K, Sommer H, Mlekmohmmdi M, Kentenich CH, Forstpointner R, Geuenich S, Bischoff J, Hiddemnn W, Heinemnn V: Weekly docetxel (Txotere) in ptients with metsttic brest cncer. Ann Oncol 2001; 12: Burstein HJ, Mnol J, Younger J, Prker LM, Bunnell CA, Scheib R, Mtulonis UA, Grber JE, Clrke KD, Shulmn LN, Winer EP: Docetxel dministered on weekly bsis for metsttic brest cncer. J Clin Oncol 2000; 18: River E, Meji JA, Arun BK, Adinin RB, Wlters RS, Brewster A, Broglio KR, Yin G, Esmeli B, Hortobgyi GN, Vlero V: Phse 3 study compring the use of docetxel on n every-3-week versus weekly schedule in the tretment of metsttic brest cncer. Cncer 2008; 2: Tbernero J, Climent MA, Lluch A, Albnell J, Vermorken JB, Brnds A, Anton A, Lurent C, Myordomo JI, Estun N, Los I, Guillem V, Grci-Conde J, Tisire JL, Bselg J: A multicentre, rndomised phse II study of weekly or 3-weekly docetxel in ptients with metsttic brest cncer. Ann Oncol 2004; 15: Slminen E, Bergmn M, Huhtl S, Ekholm E: Docetxel: stndrd recommended dose of 100 mg/m(2) is effective but not fesible for some metsttic brest cncer ptients hevily pretreted with chemotherpy phse II single-center study. J Clin Oncol 1999; 17: Mvroudis D, Alexopoulos A, Zirs N, Mlmos N, Kouroussis C, Kkolyris S, Agelki S, Klbkis K, Tsvris N, Potminou A, Rigtos G, Georgoulis V: Front-line tretment of dvnced brest cncer with docetxel nd epirubicin: multicenter phse II study. Ann Oncol 2000; : Pgni O, Sess C, Nole F, Crivellri D, Lombrdi D, Thurlimnn B, Hess D, Borner M, Buer J, Mrtinelli G, Grffeo R, Zucchetti M, D Inclci M, Goldhirsch A: Epidoxorubicin nd docetxel s first-line chemotherpy in ptients with dvnced brest cncer: multicentric phse I II study. Ann Oncol 2000; : Mill-Sntos A, Mill L, Rllo L, Solno V: High-dose epirubicin plus docetxel t stndrd dose with lenogrstim support s firstline therpy in dvnced brest cncer. Am J Clin Oncol 2001; 24: Morles S, Lorenzo A, Rmos M, Bllesteros P, Mendez M, Almnz C, Cstellnos J, Moreno-Nogueir JA, Csl J, Lizon J, Oltr A, Fru A, Mchengs I, Gln A, Belon J, Llorc C: Docetxel plus epirubicin is highly ctive, well-tolerted, first-line chemotherpy for metsttic brest cncer: Results of lrge, multicentre phse II study. Cncer Chemother Phrmcol 2004; 53: Gmucci T, D Ottvio AM, Mgnolfi E, Brdugni M, Vccro A, Sperduti I, Moscetti L, Belli F, Meliffi L: Weekly epirubicin plus docetxel s first-line tretment in metsttic brest cncer. Br J Cncer 2007; 97: Perez-Mng G, Lopez P, Sncho J, Mendez M, Cssinello J, Dominguez S, Enrech S, Plomero M, Menendez P, Quiben R, Lopez- Mrtin J: Phse II study of weekly docetxel nd doxorubicin s first-line tretment of loclly dvnced or metsttic brest cncer: preliminry results. Proc Am Soc Clin Oncol 2000; 19: Ajni JA, Welch SR, Rber MN, Fields WS, Krkoff IH: Comprehensive criteri for ssessing therpy-induced toxicity. Cncer Invest 1990; 8: Kpln EL, Meier P: Nonprmetric estimtion from incomplete observtions. J Am Stt Assoc 1959; 53: Cox DR: The Anlysis of Binry Dt. London, Methuen, Stemmler et l.
Efficacy of Pembrolizumab in Patients With Advanced Melanoma With Stable Brain Metastases at Baseline: A Pooled Retrospective Analysis
Efficcy of Pembrolizumb in Ptients With Advnced Melnom With Stble Brin Metstses t Bseline: A Pooled Retrospective Anlysis Abstrct 1248PD Hmid O, Ribs A, Dud A, Butler MO, Crlino MS, Hwu WJ, Long GV, Ancell
More informationCheckMate 153: Randomized Results of Continuous vs 1-Year Fixed-Duration Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer
CheckMte 53: Rndomized Results of Continuous vs -Yer Fixed-Durtion Nivolumb in Ptients With Advnced Non-Smll Cell Lung Cncer Abstrct 297O Spigel DR, McCleod M, Hussein MA, Wterhouse DM, Einhorn L, Horn
More informationA review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital
MEDICAL ONCOLOGY A review of the ptterns of docetxel use for hormone-resistnt prostte cncer t the Princess Mrgret Hospitl S.N. Chin MD,* L. Wng MSc, M. Moore MD,* nd S.S. Sridhr MD MSc* ABSTRACT Bckground
More informationOriginal Article. Breast Care 2016;11: DOI: /
Originl Article Brest Cre 2016;11:323 327 DOI: 10.1159/000452079 Published online: October 24, 2016 Neodjuvnt Chemotherpy with Docetxel, Crbopltin nd Weekly Trstuzumb Is Active in HER2-Positive Erly Brest
More informationIntroduction. These patients benefit less from conventional chemotherapy than patients identified as MMR proficient or microsatellite stable 3-5
Nivolumb + Ipilimumb Combintion in Ptients With DNA Mismtch Repir-Deficient/Microstellite Instbility-High Metsttic Colorectl Cncer: First Report of the Full Cohort From CheckMte-142 Abstrct 553 André T,
More informationClinical Study Report Synopsis Drug Substance Naloxegol Study Code D3820C00018 Edition Number 1 Date 01 February 2013 EudraCT Number
EudrCT Number 2012-001531-31 A Phse I, Rndomised, Open-lbel, 3-wy Cross-over Study in Helthy Volunteers to Demonstrte the Bioequivlence of the Nloxegol 25 mg Commercil nd Phse III Formultions nd to Assess
More informationEfficacy of Sonidegib in Patients With Metastatic BCC (mbcc)
AAD 216 eposter 3368 Efficcy of Sonidegib in Ptients With Metsttic BCC (mbcc) Colin Morton, 1 Michel Migden, 2 Tingting Yi, 3 Mnish Mone, 3 Dlil Sellmi, 3 Reinhrd Dummer 4 1 Stirling Community Hospitl,
More informationSYNOPSIS Final Abbreviated Clinical Study Report for Study CA ABBREVIATED REPORT
Finl Arevited Clinicl Study Report Nme of Sponsor/Compny: Bristol-Myers Squi Ipilimum Individul Study Tle Referring to the Dossier (For Ntionl Authority Use Only) Nme of Finished Product: Yervoy Nme of
More informationSponsor / Company: Sanofi Drug substance(s): AVE0005 (aflibercept)
These results re supplied for informtionl purposes only. Prescribing decisions should be mde bsed on the pproved pckge insert in the country of prescription. Sponsor / Compny: Snofi Drug substnce(s): AVE0005
More informationThe RUTHERFORD-2 trial in heterozygous FH: Results and implications
The RUTHERFORD-2 tril in heterozygous FH: Results nd implictions Slide deck kindly supplied s n eductionl resource by Professor Derick Rl MD PhD Crbohydrte & Lipid Metbolism Reserch Unit University of
More informationPrognostic significance of pretreatment serum levels of albumin, LDH and total bilirubin in patients with nonmetastatic
Crcinogenesis, 2015, Vol. 36, No. 2, 243 248 doi:10.1093/crcin/bgu247 Advnce Access publiction December 18, 2014 Originl Mnuscript originl mnuscript Prognostic significnce of pretretment serum levels of
More informationIMpower133: Primary PFS, OS, and safety in a Ph1/3 study of 1L atezolizumab + carboplatin + etoposide in extensive-stage SCLC
IMpower133: Primry PFS, OS, nd sfety in Ph1/3 study of 1L tezolizumb + crbopltin + etoposide in extensive-stge SCLC S. V. Liu, 1 A. S. Mnsfield, 2 A. Szczesn, 3 L. Hvel, 4 M. Krzkowski, 5 M. J. Hochmir,
More informationClinical Study. Oncology 2006;71:32 39 DOI: /
Oncology Clinicl Study Oncology 2006;71:32 39 DOI: 10.1159/000100447 Received: My 29, 2006 Accepted fter revision: December 9, 2006 Published online: Mrch 5, 2007 Efficcy of Consolidtion High-Dose Chemotherpy
More informationSupplementary Online Content
Supplementry Online Content Zulmn DM, Pl Chee C, Ezeji-Okoye SC, et l. Effect of n intensive outptient progrm to ugment primry cre for high-need Veterns Affirs ptients: rndomized clinicl tril. JAMA Intern
More informationGemmis Injection 38 mg/ml
Gemmis Injection 8 mg/ml Gemcitbine (Gemcitbine HCl) is nucleoside nlogue tht exhibits nti-tumor ctivity. The empiricl formul for Gemcitbine HCl is C 9H 11F 2N O.HCl. It hs moleculr weight of 299.66. Gemcitbine
More informationSafety and Tolerability of Subcutaneous Sarilumab and Intravenous Tocilizumab in Patients With RA
Sfety nd Tolerbility of Subcutneous Srilumb nd Intrvenous Tocilizumb in Ptients With RA Pul Emery, 1 Jun Rondon, 2 Anju Grg, 3 Hubert vn Hoogstrten, 3 Neil M.H. Grhm, 4 Ming Liu, 4 Nncy Liu, 3 Jnie Prrino,
More informationSee 17 for PATIENT COUNSELING INFORMATION. Revised: 02/2011 FULL PRESCRIBING INFORMATION: CONTENTS*
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use GEMZAR sfely nd effectively. See full prescribing informtion for GEMZAR. GEMZAR (gemcitbine for injection)
More informationClinical Evidence for Second- and Third-Line Treatment Options in Advanced Non-Small Cell Lung Cancer
Clinicl Evidence for Second- nd Third-Line Tretment Options in Advnced Non-Smll Cell Lung Cncer Filippo de Mrinis, Frncesco Grossi b Thorcic Oncology Unit I, Deprtment of Lung Diseses, Sn Cmillo nd Forlnini
More informationSee 17 for PATIENT COUNSELING INFORMATION. Revised: 09/2017 FULL PRESCRIBING INFORMATION: CONTENTS*
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use Gemzr sfely nd effectively. See full prescriing informtion for Gemzr. GEMZAR (gemcitine for injection),
More informationReference Slide Deck. Abstract 553 Abstract 554 Abstract 560
Clinicl Spotlight Immunotherpy Advnces for Colorectl Crcinom in 2018: Newly Relesed Dt From the Gstrointestinl Cncers Symposium in Sn Frncisco Reference Slide Deck Abstrct 553 Abstrct 554 Abstrct 560 Mismtch
More informationStart ORKAMBI today. INDICATIONS AND USAGE IMPORTANT SAFETY INFORMATION. Sydney Age 4
F O R H E A L T H C A R E P R O F E S S I O N A L S For ptients ge 2 yers nd older who re homozygous for the F508del muttion 1,2 Modify the course. Strt tody. Sydney Age 4 F508del/F508del INDICATIONS AND
More informationDOSAGE FORMS AND STRENGTHS HIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ALIMTA sfely nd effectively. See full prescribing informtion for ALIMTA. ALIMTA (pemetrexed disodium)
More informationEmerging Options for Thromboprophylaxis After Orthopedic Surgery: A Review of Clinical Data
Emerging Options for Thromboprophylxis After Orthopedic Surgery: A Review of Clinicl Dt Bob L. Lobo, Phrm.D. In four rndomized, controlled studies of ptients undergoing orthopedic surgery, the ntithrombotic
More informationSee 17 for PATIENT COUNSELING INFORMATION and FDAapproved
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ALIMTA sfely nd effectively. See full prescribing informtion for ALIMTA. ALIMTA (pemetrexed for injection),
More informationPNEUMOVAX 23 is recommended by the CDC for all your appropriate adult patients at increased risk for pneumococcal disease 1,2 :
PNEUMOVAX 23 is recommended y the CDC for ll your pproprite dult ptients t incresed risk for pneumococcl disese 1,2 : Adults ged
More informationMOLECULAR AND CLINICAL ONCOLOGY 5: , 2016
MOLECULAR AND CLINICAL ONCOLOGY 5: 429-436, 2016 Improvement of survivl with postmstectomy rdiotherpy in ptients with 1-3 positive xillry lymph nodes: A systemtic review nd met-nlysis of the current literture
More informationTR Spitzer 1, CJ Friedman 2, W Bushnell 2, SR Frankel 3, J Raschko 4. Summary:
(2000) 26, 203 210 2000 Mcmilln Publishers Ltd All rights reserved 0268 3369/00 $15.00 www.nture.com/bmt Double-blind, rndomized, prllel-group study on the efficcy nd sfety of orl grnisetron nd orl ondnsetron
More informationAdverse Events Grading Card
Adverse Events Grding Crd Common Terminology Criteri for Adverse Events* In clinicl studies, 2 of the most common dverse events reported with ALAVEN were peripherl neuropthy nd neutropeni. 1 With this
More informationOlanzapine for the prophylaxis and rescue of chemotherapyinduced nausea and vomiting (CINV): a retrospective study
Originl Article Olnzpine for the prophylxis nd rescue of chemotherpyinduced nuse nd vomiting (CINV): retrospective study Leonrd Chiu, Nichols Chiu, Ronld Chow, Liying Zhng, Mrk Psetk, Jordn Stinson, Brenne
More informationR Martino 1, P Romero 1, M Subirá 1, M Bellido 1, A Altés 1, A Sureda 1, S Brunet 1, I Badell 2, J Cubells 2 and J Sierra 1
Bone Mrrow Trnsplnttion, (1999) 24, 283 287 1999 Stockton Press All rights reserved 0268 3369/99 $12.00 http://www.stockton-press.co.uk/bmt Comprison of the clssic Glucksberg criteri nd the IBMTR Severity
More informationImmune-Mediated Adverse Reactions Management Guide
Immune-Medited Adverse Rections Mngement Guide INDICATIONS AND USAGE YERVOY (ipilimumb) is indicted for: Tretment of unresectble or metsttic melnom in dults nd peditric ptients (12 yers nd older) Adjuvnt
More informationA retrospective study on combination therapy with ifosfamide, adriamycin and cisplatin for progressive or recurrent uterine sarcoma
MOLECULAR AND CLINICAL ONCOLOGY 2: 591-595, 2014 A retrospective study on combintion therpy with ifosfmide, drimycin nd cispltin for progressive or recurrent uterine srcom WATARU YAMAGAMI, NOBUYUKI SUSUMU,
More informationOne of the most important biological mechanisms of
Brief Report Serum Thymidine Kinse 1 Activity in the Prognosis nd Monitoring of Chemotherpy in Lung Cncer Ptients: A Brief Report Benjmin Nismn, PhD,* Hovv Nechushtn, MD, PhD,* Him Birn, MD, Hds Gntz-Sorotsky,
More informationClinicalTrials.gov Identifier: NCT
Efficcy of Drtumumb, Lenlidomide, nd Dexmethsone Versus Lenlidomide nd Dexmethsone in Relpsed or Refrctory Multiple Myelom Ptients With to 3 Prior Lines of Therpy: Updted Anlysis of POLLUX Sd Z. Usmni,
More informationPegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi s sarcoma
REVIEW Pegylted liposoml doxorubicin in the tretment of AIDS-relted Kposi s srcom Ashish Udhrin 1 Keith M Skubitz 2 Donld W Northfelt 3 1 Deprtment of Medicine, Myo Clinic Arizon, AZ, USA; 2 Division of
More informationLung cancer is the most common cause of cancer deaths in
Originl Article A Phse I/II Study of Bortezomib in Combintion with Pclitxel, Crbopltin, nd Concurrent Thorcic Rdition Therpy for Non Smll-Cell Lung Cncer North Centrl Cncer Tretment Group (NCCTG)-N0321
More informationAbstract. Background. Aim. Patients and Methods. Patients. Study Design
Impct of the Use of Drugs nd Substitution Tretments on the Antivirl Tretment of Chronic Heptitis C: Anlysis of Complince, Virologicl Response nd Qulity of Life (CHEOBS). Melin, 1 J.-. Lng, D. Ouzn, 3 M.
More informationAge related differences in prognosis and prognostic factors among patients with epithelial ovarian cancer
MOLECULAR AND CLINICAL ONCOLOGY 9: 329-334, 2018 Age relted differences in prognosis nd prognostic fctors mong ptients with epithelil ovrin cncer KENJI YOSHIKAWA, TAKESHI FUKUDA, RYO UEMURA, HIROAKI MATSUBARA,
More informationUniversity of Texas Health Science Center, San Antonio, San Antonio, Texas, USA
Lung Cncer Chemotherpy Given Ner the End of Life by Community Oncologists for Advnced Non-Smll Cell Lung Cncer Jose R. Murillo, Jr., Jim Koeller b,c Methodist Hospitl, Houston, Texs, USA; b University
More informationImpact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors
Originl Article Impct of Positive Nodl Metstses in Ptients with Thymic Crcinom nd Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, nd Jennifer L. Sullivn, MD Introduction: Thymic crcinoms
More informationLung cancer is the leading cause of cancer death worldwide, EGFR Mutation and Brain Metastasis in Pulmonary Adenocarcinomas
Originl Article EGFR Muttion nd Brin Metstsis in Pulmonry Adenocrcinoms Dong-Yeop Shin, MD,* Im Il N, MD,* Cheol Hyeon Kim, MD, PhD, Sunhoo Prk, MD, PhD, HeeJong Bek, MD, PhD, nd Sung Hyun Yng, MD, PhD*
More informationFULL PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use Herceptin sfely nd effectively. See full prescriing informtion for Herceptin. HERCEPTIN (trstuzum)
More informationPROFILE OF A PATIENT WITH mbc with visceral metastases
Ptient P.V. PRFILE F A PATIENT WIT mbc with viscerl metstses Indiction Metsttic Brest Cncer ALAVEN (eribulin mesylte) Injection is indicted for the tretment of ptients with metsttic brest cncer (mbc) who
More informationSee 17 for PATIENT COUNSELING INFORMATION and FDAapproved. Revised: 01/2019
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ALIMTA sfely nd effectively. See full prescribing informtion for ALIMTA. ALIMTA (pemetrexed for injection),
More informationUsing Paclobutrazol to Suppress Inflorescence Height of Potted Phalaenopsis Orchids
Using Pcloutrzol to Suppress Inflorescence Height of Potted Phlenopsis Orchids A REPORT SUBMITTED TO FINE AMERICAS Linsey Newton nd Erik Runkle Deprtment of Horticulture Spring 28 Using Pcloutrzol to Suppress
More informationHERCEPTIN (trastuzumab) Intravenous Infusion Initial U.S. Approval: 1998
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively. See full prescriing informtion for. HERCEPTIN (trstuzum) Intrvenous Infusion
More informationCheckMate-142 Study Design
Nivolumb + Ipilimumb Combintion in Ptients With DNA Mismtch Repir-Deficient/Microstellite Instbility-High Metsttic Colorectl Cncer: First Report of the Full Cohort From CheckMte-142 Thierry André, 1 Sr
More informationRevised: 6/2018 History of severe hypersensitivity reaction to pemetrexed. (4)
HIGHLIGHTS OF PRESCRIBING INFORMATION ------------------------ WARNINGS AND PRECAUTIONS ----------------------- These highlights do not include ll the informtion needed to use ALIMTA sfely nd effectively.
More informationOpioid Use and Survival at the End of Life: A Survey of a Hospice Population
532 Journl of Pin nd Symptom Mngement Vol. 32 No. 6 December 2006 NHPCO Originl Article Opioid Use nd Survivl t the End of Life: A Survey of Hospice Popultion Russell K. Portenoy, MD, Un Sibircev, BA,
More informationImpact of Pharmacist Intervention on Diabetes Patients in an Ambulatory Setting
Impct of Phrmcist Intervention on Dibetes Ptients in n Ambultory Setting Julie Stding, PhrmD, CDE, Jmie Herrmnn, PhrmD, Ryn Wlters, MS, Chris Destche, PhrmD, nd Aln Chock, PhrmD Dibetes is the seventh-leding
More informationThe incidence of melanoma, the most serious
Efectiveness nd sfety of ipilimumb therpy in dvnced melnom: evidence from clinicl prctice sites in the US Kim A Mrgolin, MD, Ahmd Trhini, MD, PhD, b Sumti Ro, PhD, c Monic Ktyl, JD, MPH, d I-Fen Chng,
More informationComparative Safety of Filgrastim versus Sargramostim in Patients Receiving Myelosuppressive Chemotherapy
Comprtive Sfety of Filgrstim versus Srgrmostim in Ptients Receiving Myelosuppressive Chemotherpy Gry Milkovich, B.S., Ronld J. Moleski, Phrm.D., John F. Reitn, Phrm.D., Dvid M. Dunning, M.D., Gene A. Gibson,
More informationFirst-line and Maintenance Treatment with ALIMTA therapy for advanced nonsquamous non-small cell lung cancer (NSCLC)
YOUR LIFE. First-line nd Mintennce Tretment with ALIMTA therpy for dvnced nonsqumous non-smll cell lung cncer (NSCLC) ALIMTA is pproved by the FDA in combintion with cispltin (nother chemotherpy drug)
More informationYERVOY (ipilimumab) injection, for intravenous use Initial U.S. Approval: 2011
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively. See full prescribing informtion for. (ipilimumb) injection, for intrvenous use
More informationSensor-controlled scalp cooling to prevent chemotherapy-induced alopecia in female cancer patients
ORIGINAL ARTICLE Sensor-controlled sclp cooling to prevent chemotherpy-induced lopeci in femle cncer ptients M.K. Fehr md,* J. Welter mph,* W. Sell md,* R. Jung,* nd R. Felberbum md ABSTRACT Bckground
More informationUsing proliferative markers and Oncotype DX in therapeutic decision-making for breast cancer: the B.C. experience
ORIGINAL ARTICLE Using prolifertive mrkers nd Oncotype DX in therpeutic decision-mking for brest cncer: the B.C. experience E. Bxter bsc,* L. Gondr btech pdc, C. Lohrisch md, S. Chi md, K. Gelmon md, M.
More informationEsophageal carcinoma is the eighth most common cancer
ORIGINAL ARTICLE Tumor-Strom Rtio Is n Independent Predictor for Survivl in Esophgel Squmous Cell Crcinom Ki Wng, MD,* Wei M, MD,* Jinbo Wng, MD,* Ling Yu, MD, Xiomei Zhng, MD, Zhenbo Wng, MD, Bingxu Tn,
More informationHIGHLIGHTS OF PRESCRIBING INFORMATION
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ALIMTA sfely nd effectively. See full prescriing informtion for ALIMTA. ALIMTA (pemetrexed for injection)
More informationAddendum to the Evidence Review Group Report on Aripiprazole for the treatment of schizophrenia in adolescents (aged years)
Addendum to the Evidence Review Group Report on Aripiprzole for the tretment of schizophreni in dolescents (ged 15-17 yers) Produced by Authors Correspondence to Southmpton Helth Technology Assessments
More informationORIGINAL ARTICLE ABSTRACT INTRODUCTION
ORIGINAL ARTICLE LOSS OF EPCAM STAINING CORRELATES WITH POOR OUTCOME IN CRC, Wng et l. Reduction in membrnous immunohistochemicl stining for the intrcellulr domin of epithelil cell dhesion molecule correltes
More informationManagement of Relapsed/Refractory Follicular Lymphoma
April 2018 Volume 16, Issue 4, Supplement 10 Mngement of Relpsed/Refrctory Folliculr Lymphom n How I Tret Relpsed/Refrctory Folliculr Lymphom: An Expert Perspective n Highlights from: The 2017 Americn
More informationThe Role of Intraoperative Radiation Therapy (IORT) in the Treatment of Locally Advanced Gynecologic Malignancies
The Role of Intropertive Rdition Therpy (IORT) in the Tretment of Loclly Advnced Gynecologic Mlignncies MARCELA G. DEL CARMEN, JAMES F. MCINTYRE, b ANNEKATHRYN GOODMAN Vincent Gynecologic Oncology Service,
More informationMulticenter Randomized Phase 2 Clinical Trial of a Recombinant Human Endostatin Adenovirus in Patients with Advanced Head and Neck Carcinoma
The Americn Society of Gene & Cell Therpy originl rticle Multicenter Rndomized Phse Clinicl Tril of Recombinnt Humn Endosttin Adenovirus in Ptients with Advnced Hed nd Neck Crcinom Wen Ye, Rnyi Liu, Chngchun
More informationOriginal Article. T Akter 1, N Islam 2, MA Hoque 3, S Khanam 4, HA khan 5, BK Saha 6. Abstract:
Fridpur Med. Coll. J. 214;9(2):61-67 Originl Article Nebuliztion by Isotonic Mgnesium Sulphte Solution with Provide Erly nd Better Response s Compred to Conventionl Approch ( Plus Norml Sline) in Acute
More informationCase Report INTRODUCTION CASE REPORT. pissn eissn X
pissn 2287-2728 eissn 2287-285X Cse Report Clinicl nd Moleculr Heptology 2018;24:424-429 Complete cure of dvnced heptocellulr crcinom with right drenl glnd metstsis nd portl vein thrombosis by multiple
More informationSeasonal influenza vaccination programme country profile: Ireland
Sesonl influenz vccintion progrmme country profile: Irelnd 2012 13 Seson Bckground informtion Influenz immunistion policy nd generl fcts bout Irelnd Volume indices of GDP per cpit in 2011 nd 2013 (EU-
More informationMetabolic Syndrome and Health-related Quality of Life in Obese Individuals Seeking Weight Reduction
Metbolic Syndrome nd Helth-relted Qulity of Life in Obese Individuls Seeking Weight Reduction Adm Gilden Tsi 1, Thoms A. Wdden 1, Dvid B. Srwer 1, Robert I. Berkowitz 1, Leslie G. Womble 1, Louise A. Hesson
More informationA cross-sectional and follow-up study of leukopenia in tuberculosis patients: prevalence, risk factors and impact of anti-tuberculosis
Originl Article A cross-sectionl nd follow-up study of leukopeni in tuberculosis ptients: prevlence, risk fctors nd impct of nti-tuberculosis tretment Fei-Shen Lin 1 *, Mei-Ying Wu 2 *, Wen-Jun Tu 3, Hong-Qiu
More informationInvasive Pneumococcal Disease Quarterly Report. July September 2017
Invsive Pneumococcl Disese Qurterly Report July September 2017 Prepred s prt of Ministry of Helth contrct for scientific services by Rebekh Roos Helen Heffernn October 2017 Acknowledgements This report
More information1 Indications and Usage
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use ERBITUX sfely nd effectively. See full prescriing informtion for ERBITUX. ERBITUX (cetuxim) injection,
More informationY. Yazici 1, D. Moniz Reed 2, C. Klem 2, L. Rosenblatt 2, G. Wu 2, J.M. Kremer 3
Greter remission rtes in ptients with erly versus long-stnding disese in biologic-nive rheumtoid rthritis ptients treted with btcept: post hoc nlysis of rndomised clinicl tril dt Y. Yzici 1, D. Moniz Reed
More informationkey words: bortezomib, multiple myeloma, retrospective analysis, treatment outcomes, subcutaneous, intravenous
reserch report Effect of Route of Bortezomib Administrtion on Tretment Outcomes in Previously Untreted Ptients with Multiple Myelom: A Retrospective Anlysis from US Community Oncology Prctices Robert M
More informationXALKORI (crizotinib) Is Available Through Specialty Pharmacies
XALKORI (crizotinib) Is Avilble Through Specilty Phrmcies Specilty Phrmcy Ordering Process The Provider s Office Submits XALKORI prescriptions to the specilty phrmcy vi: Phone Fx Internet Submits ny supporting
More informationTumor Vascularity Does Not Predict Response to Yttrium-90 Radioembolization for Hepatic Metastases from Colorectal Cancer
Originl Article 3 Tumor Vsculrity Does Not Predict Response to Yttrium-90 Rdioemboliztion for Heptic Metstses from Colorectl Cncer Alipi V. Nydenov Willim P. Hrris 2 Guy E. Johnson 3 Dniel S. Hippe 4 Siddhrth
More informationThe Acute Time Course of Concurrent Activation Potentiation
Mrquette University e-publictions@mrquette Exercise Science Fculty Reserch nd Publictions Exercise Science, Deprtment of 1-1-2010 The Acute Time Course of Concurrent Activtion Potentition Luke Grceu Mrquette
More informationCommunity. Profile Yellowstone County. Public Health and Safety Division
Community Helth Profile 2015 Yellowstone County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationPRACTICE GUIDELINE SERIES
PRACTICE GUIDELINE SERIES 131 I Tositumom in lymphom M.C. Cheung MD,* J.A. McEchern MD,* A.E. Hynes,* R.M. Meyer MD,* K. Imrie md* nd the Memers of the Hemtology Disese Site Group # of Cncer Cre Ontrio
More informationCommunity. Profile Lewis & Clark County. Public Health and Safety Division
Community Helth Profile 2015 Lewis & Clrk County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationEFFECTS OF INGREDIENT AND WHOLE DIET IRRADIATION ON NURSERY PIG PERFORMANCE
Swine Dy 21 EFFECTS OF INGREDIENT AND WHOLE DIET IRRADIATION ON NURSERY PIG PERFORMANCE J. M. DeRouchey, M. D. Tokch, J. L. Nelssen, R. D. Goodbnd, S. S. Dritz 1, J. C. Woodworth, M. J. Webster, B. W.
More informationCommunity. Profile Missoula County. Public Health and Safety Division
Community Helth Profile 2015 Missoul County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationMOLECULAR AND CLINICAL ONCOLOGY 7: , 2017
336 Effect of intrtumorl bscess/necrosis on the outcome for hed nd neck cncer ptients treted by hypofrctionted stereotctic re irrdition using CyberKnife HIDEYA YAMAZAKI 1,2, MIKIO OGITA 3, KENGO HIMEI
More informationCommunity. Profile Big Horn County. Public Health and Safety Division
Community Helth Profile 2015 Big Horn County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl
More informationCommunity. Profile Powell County. Public Health and Safety Division
Community Helth Profile 2015 Powell County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12 Behviorl Risk
More informationGranulocytopenic Cancer Patients
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, JUIY 1986, P. 64-68 0066-4804/86/070064-05$02.00/0 Copyright 1986, Americn Society for Microbiology Vol. 30, No. 1 Rndomized Comprison between Two Ceftzidime-Contining
More informationFor Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)
For Adults With Previously Treted Advnced Non-Smll Cell Lung Cncer (NSCLC) individuls depicted re models used for illustrtive purposes only. It cn be overwhelming to lern tht your previously treted dvnced
More informationPatient Monitoring Checklist
Ptient Monitoring Checklist Ptient nme Dte This checklist is intended for nurses or other helthcre professionls (HCPs) to use prior to dosing ech ptient nd t ny follow-up visits or clls with the ptient
More informationIn the treatment of cardiovascular disease (CVD), national
n report n Beyond LDL Cholesterol: The Role of Elevted Triglycerides nd Low HDL Cholesterol in Residul CVD Risk Remining After Sttin Therpy Peter Algon Jr, MD, FACC In the tretment of crdiovsculr disese
More informationP (RCC) was first done in the late 1930s and reported in
Pulmonry Resection of Metsttic Renl Cell Crcinom Robert J. Cerfolio, MD, Mrk S. Allen, MD, Clude Deschmps, MD, Richrd C. Dly, MD, Steven L. Wllrichs, BS, Victor F. Trstek, MD, nd Peter C. Pirolero, MD
More informationAnalysis of alternatives for insulinizing patients to achieve glycemic control and avoid accompanying risks of hypoglycemia
284 Anlysis of lterntives for izing ptients to chieve glycemic control nd void ccompnying risks of hypoglycemi JIALIN GAO 1,2*, QIANYIN XIONG 1,2*, JUN MIAO 1*, YAO ZHANG 2,3, LIBING XIA 1, MEIQIN LU 1,
More informationSummary of Package Insert 1
Summry of Pckge Insert 1 For Sttes with Non-Published Policies Indictions Non-infected prtil nd full-thickness skin ulcers due to VSU 2 of greter thn 1 month durtion nd which hve not dequtely responded
More informationSupplementary Online Content
Supplementry Online Content Rieckmnn N, Kronish IM, Shpiro PA, Whng W, Dvidson KW. Serotonin reuptke inhibitor use, depression, nd long-term outcomes fter n cute coronry : prospective cohort study. JAMA
More informationComparison of autologous peripheral blood stem cell dosing by ideal vs actual body weight
Bone Mrrow Trnsplnttion, (1999) 23, 867 873 1999 Stockton Press All rights reserved 0268 3369/99 $12.00 http://www.stockton-press.co.uk/bmt Comprison of utologous peripherl blood stem cell dosing by idel
More informationTrends in antihypertensive and lipidlowering therapy in subjects with type II diabetes: clinical effectiveness or clinical discretion?
ORIGINAL ARTICLE Trends in ntihypertensive nd lipidlowering therpy in subjects with type II dibetes: clinicl effectiveness or clinicl discretion? MC Gulliford, J Chrlton nd R Ltinovic Deprtment of Public
More informationAsian Journal of Andrology (2017) 19,
(2017) 19, 20 25 2017 AJA, SIMM & SJTU. All rights reserved 1008-682X www.sindro.com; www.jndrology.com Prostte Cncer Open Access ORIGINAL ARTICLE Refining the Americn Urologicl Assocition nd Americn Society
More informationCommunity. Profile Anaconda- Deer Lodge County. Public Health and Safety Division
Community Helth Profile 2015 Ancond- Deer Lodge County Public Helth nd Sfety Division Tble of Contents Demogrphic Informtion 1 Communicble Disese 3 Chronic Disese 4 Mternl nd Child Helth 10 Mortlity 12
More informationFor Adults with Metastatic Melanoma
For Adults with Metsttic Melnom The + YERVOY Regimen ws shown to reduce the risk of disese progression by nerly 60% compred to YERVOY lone. Hlf of the ptients on + YERVOY were live t 11.5 months without
More informationCapecitabine in the treatment of metastatic renal cell carcinoma
British Journl of Cncer (2000) 83(5), 583 587 doi: 10.1054/ bjoc.2000.1340, vilble online t http://www.idelibrry.com on Cpecitbine in the tretment of metsttic renl cell crcinom K Oevermnn 1, J Buer 1,
More informationSee 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Revised: 10/2017
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include ll the informtion needed to use sfely nd effectively. See full prescribing informtion for. (ipilimumb) injection, for intrvenous use
More informationFertility in Norwegian testicular cancer patients
DOI: 0.054/ bjoc.999.0989, vilble online t http://www.idelibrry.com on Fertility in Norwegin testiculr cncer ptients SD Fosså nd Ø Krvdl 2 The Norwegin Rdium Hospitl, Montebello, N-030 Oslo, Norwy; 2 The
More information